Removab contains the trifunctional antibody, Catumaxomab, which through its targeted mechanism of action destroys cells from EpCAM positive carcinomas. The antibody recognizes a protein on the surface of cancer cells, the so-called EpCAM molecule. It simultaneously recruits immune cells, and activates them to destroy the cancer cells.

Removab is used to treat malignant ascites in patients when standard treatment is not available or is no longer feasible.

Malignant ascites is an accumulation of fluid in the abdominal cavity (peritoneal cavity) resulting from certain types of cancer, such as carcinomas.

Removab was developed in cooperation with TRION Pharma GmbH. Fresenius Biotech holds the EU Marketing Authorization and worldwide marketing rights for Removab.